Trial · NCT00901901
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival | Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva) | 289 | 95% Confidence Interval 250 to 321 | Days | |
| Overall Survival | Sorafenib (Nexavar, BAY43-9006) + Placebo | 259 | 95% Confidence Interval 226 to 322 | Days | |
| Time to Radiological Tumor Progression (TTP) | Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) | 97 | 95% Confidence Interval 82 to 126 | Days | |
| Time to Radiological Tumor Progression (TTP) | Sorafenib (Nexavar, BAY 43-9006) + Placebo | 122 | 95% Confidence Interval 88 to 136 | Days | |
| Disease Control | Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) | 159 | Participants | ||
| Disease Control | Sorafenib (Nexavar, BAY 43-9006) + Placebo | 188 | Participants | ||
| Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index | Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) | cycle1 | 0.777 | 95% Confidence Interval 0.760 to 0.795 | Scores on a scale |
| Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index | Sorafenib (Nexavar, BAY 43-9006) + Placebo | cycle1 | 0.774 | 95% Confidence Interval 0.757 to 0.790 | Scores on a scale |
| Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index | Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) | cycle2 | 0.753 | 95% Confidence Interval 0.735 to 0.771 | Scores on a scale |
| Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index | Sorafenib (Nexavar, BAY 43-9006) + Placebo | cycle2 | 0.749 | 95% Confidence Interval 0.732 to 0.766 | Scores on a scale |
| Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index | Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) | cycle3 | 0.728 | 95% Confidence Interval 0.708 to 0.748 | Scores on a scale |
| Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index | Sorafenib (Nexavar, BAY 43-9006) + Placebo | cycle3 | 0.724 | 95% Confidence Interval 0.706 to 0.743 | Scores on a scale |
| Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index | Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) | cycle4 | 0.704 | 95% Confidence Interval 0.681 to 0.726 | Scores on a scale |
| Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index | Sorafenib (Nexavar, BAY 43-9006) + Placebo | cycle4 | 0.700 | 95% Confidence Interval 0.678 to 0.721 | Scores on a scale |
| Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index | Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) | cycle5 | 0.679 | 95% Confidence Interval 0.653 to 0.705 | Scores on a scale |
| Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index | Sorafenib (Nexavar, BAY 43-9006) + Placebo | cycle5 | 0.675 | 95% Confidence Interval 0.650 to 0.700 | Scores on a scale |
| Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index | Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) | cycle6 | 0.654 | 95% Confidence Interval 0.625 to 0.684 | Scores on a scale |
| Health-related Quality of Life and Utility Values as Measured by EQ-5D - Index | Sorafenib (Nexavar, BAY 43-9006) + Placebo | cycle6 | 0.651 | 95% Confidence Interval 0.622 to 0.679 | Scores on a scale |
| Health-related Quality of Life and Utility Values as Measured by EQ-5D - VAS | Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) | cycle1 | 74.397 | 95% Confidence Interval 73.219 to 75.576 | Scores on a scale |
| Health-related Quality of Life and Utility Values as Measured by EQ-5D - VAS | Sorafenib (Nexavar, BAY 43-9006) + Placebo | cycle1 | 74.656 | 95% Confidence Interval 73.504 to 75.808 | Scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00901901/results